ABT-510 in Treating Patients With Metastatic Melanoma

Phase 2 Completed 42 enrolled Mayo Clinic National Cancer Institute (NCI) · collab

Open-labelTreatment

Summary

RATIONALE: ABT-510 may stop the growth of melanoma by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well giving ABT-510 works in treating patients with metastatic melanoma.

Timeline

Start: 2004-11
Primary completion: 2005-06
Completion: 2005-06

Outcome

Missed primary endpoint

paper Only 3 of the first 20 patients enrolled were progression free and on treatment at 18 weeks resulting in early termination of the study. PMID 17551310 ↗

Publications

Results Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007 Jun;30(3):303-9. doi: 10.1097/01.coc.0000256104.80089.35.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABT-510	Peptide	100 mg	Subcutaneous